Hartmut J. Ehrlich - Concepedia

Author

Hartmut J. Ehrlich

Also Known As

David J. Earp, Elkbuli A., H EHRLICH, H Ehrlich, H J Ehrlich, H. EHRLICH, H. Ehrlich, H. J. EHRLICH, H. J. Ehrlich, H.J. EHRLICH

176

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Baxter (Austria)Baxter (United States)Abivax (France)Medical University of Vienna Vienna General Hospital

About

Hartmut J. Ehrlich is an author at Baxter (Austria) specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	33	1.7K
2	Natural Sciences	7	7	471
3	Biochemistry	5	5	384
4	Allergy	4	4	275
5	Health Sciences	1	1	13

Hartmut J. Ehrlich

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh, New England Journal of Medicine	2008	274
Safety of factor VIII inhibitor bypass activity (FEIBA<sup>®</sup>): 10‐year compilation of thrombotic adverse events Hartmut J. Ehrlich, M. J. HENZL, Edward D. Gomperts Haemophilia	2002	220
Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. Christine Kost, Werner Stüber, Hartmut J. Ehrlich, Journal of Biological Chemistry	1992	139
Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies Barbara Plaimauer, Johanna A. Kremer Hovinga, Claudia Juno, Journal of Thrombosis and Haemostasis Disease MechanismAutoantibody ProductionInhibitory AntibodiesImmunologyPathology	2011	124
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. Klaus T. Preissner, J. Grulich‐Henn, Hartmut J. Ehrlich, Journal of Biological Chemistry	1990	118
A close look at human IgG sialylation and subclass distribution after lectin fractionation Johannes Stadlmann, Alfred Weber, Martin Pabst, PROTEOMICS GlycobiologyImmunologyMolecular BiologyPathologyHuman Igg Sialylation	2009	106
A Tick-borne Encephalitis Virus Vaccine Based on the European Prototype Strain Induces Broadly Reactive Cross-neutralizing Antibodies in Humans Klaus K. Orlinger, Yvonne Hofmeister, Richard Fritz, The Journal of Infectious Diseases VaccinationVaccine DevelopmentAllergyMedicineVaccine Target	2011	104
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentDose-escalation Phase 1/2Vaccine Research	2013	100
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial Perry Barrett, Gregory P. Berezuk, Sandor Fritsch, The Lancet VaccinologyVaccine SafetyCross-protectionVaccinationVaccine Development	2011	100
Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin Hartmut J. Ehrlich, Jaap Keijer, Klaus T. Preissner, Biochemistry Heparin BindingFunctional InteractionCytoskeletonHeparin ConcentrationProteomics	1991	95

Page 1